Cumberland Pharmaceuticals (CPIX) vs SCYNEXIS (SCYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cumberland Pharmaceuticals (CPIX) has outperformed SCYNEXIS (SCYX) over the past year, gaining 90.2% versus a loss of 32.1%. Over five years, CPIX leads with a +154.7% price change compared with -90.5% for SCYX. Cumberland Pharmaceuticals is the larger company by market cap ($104.6 million vs $42.0 million), about 2.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CPIX | SCYX |
|---|---|---|
| Share price | $6.98 | $4.22 |
| Market cap | $104.58M | $41.99M |
| 1-day change | +1.31% | -11.72% |
| YTD return | +75.38% | -16.53% |
| 1-year return | +90.19% | -32.11% |
| 5-year return | +154.74% | -90.53% |
| Forward P/E | 49.86 | — |
| EPS (TTM) | $-0.62 | $-0.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.28 | $9.12 |
| 52-week low | $1.85 | $3.53 |
| Distance from 52-week high | -24.78% | -53.73% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +760.90% |
| Average volume | 87.71K | 279.10K |
| Shares outstanding | 14.98M | 9.95M |
| Employees | 88 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Cumberland Pharmaceuticals is about 2.5 times larger than SCYNEXIS by market value ($104.58M vs $41.99M).
- CPIX has outperformed SCYX by 122.3 percentage points over the past year.
About Cumberland Pharmaceuticals
CPIX stock →Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
About SCYNEXIS
SCYX stock →SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.
Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees
CPIX vs SCYX FAQ
Which is bigger, Cumberland Pharmaceuticals or SCYNEXIS?
Cumberland Pharmaceuticals (CPIX) is larger, with a market capitalization of $104.58M compared with $41.99M for SCYNEXIS (SCYX).
Which stock has performed better over the past year, CPIX or SCYX?
CPIX returned +90.19% over the past 12 months, compared with -32.11% for SCYX (price return, excluding dividends). Past performance does not predict future results.
Are Cumberland Pharmaceuticals and SCYNEXIS in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.